Spyre Therapeutics (SYRE) Stock
Clinical biotech developing enzyme treatments for rare diseases. Here's the price, business snapshot, and what's worth knowing about Spyre Therapeutics in June 2026.
Aeglea Biotherapeutics (SYRE) is a clinical-stage biotechnology company with a focus on engineered enzyme therapeutics. Its work centres on developing novel biologics intended to treat rare metabolic disorders and oncology indications, where successful clinical results and regulatory approvals can materially affect valuation. With a market capitalisation of about $1.80 billion, the company attracts attention from investors seeking exposure to innovation-led growth in biotech. Important considerations for investors include the binary nature of clinical outcomes, regulatory scrutiny, potential need for additional funding, and typical sector volatility and illiquidity in small-cap biotechs. Financial performance may lag until late-stage readouts or commercialisation milestones, so time horizons and risk tolerance matter. This summary is educational only and not personalised financial advice; investors should perform their own due diligence, review regulatory filings and consult a qualified financial adviser to assess suitability for their circumstances.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying SPYRE Therapeutics stock, believing it has significant growth potential.
Financial Health
Spyre Therapeutics is performing well with strong cash flow and a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SYRE
Oncology Repurposing: Could Autoimmune Buyouts Surge?
Gilead Sciences has agreed to acquire Ouro Medicines for up to $2.175 billion to secure its advanced T-cell engager therapies. This strategic buyout reflects a growing industry trend of repurposing oncology technologies to treat severe autoimmune diseases.
Published: 24 March 2026
Explore BasketTYK2 Inhibitors: Might Oral Drugs Rule Autoimmune?
Alumis's breakthrough trial results for its oral psoriasis drug have highlighted the massive potential of advanced autoimmune therapies. This theme focuses on the pharmaceutical companies pioneering next-generation oral treatments, particularly selective TYK2 inhibitors, which represent a new frontier in convenient and effective patient care.
Published: 7 January 2026
Explore BasketRinvoq vs Humira Results | Immunology Market Shift
AbbVie's new arthritis drug, Rinvoq, has proven superior to its predecessor, Humira, signaling a major shift in the immunology market. This theme focuses on the innovative pharmaceutical companies poised to benefit from the demand for more effective autoimmune disease treatments.
Published: 21 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage pipeline
Several programmes in clinical trials can act as potential catalysts, though outcomes are binary and unpredictable.
Novel enzyme approach
Engineered enzymes aim to address metabolic and oncology needs, offering scientific promise but with execution and regulatory hurdles.
Risk and outlook
Small-cap biotech exposure can offer growth potential but brings volatility, funding and liquidity risks—suitability depends on investor goals.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
